Literature DB >> 17111186

Retinal function and histopathology in rabbits treated with Topiramate.

S Kjellström1, A Bruun, B Isaksson, T Eriksson, S Andréasson, V Ponjavic.   

Abstract

PURPOSE: To evaluate retinal function and histopathology in rabbits treated orally with the anti-epileptic drug topiramate.
METHODS: Six rabbits were treated with a daily oral dose of topiramate during a period of eight months. Six rabbits receiving water served as controls. Blood samples were analyzed for determination of topiramate serum levels in order to ensure successful drug exposition. Standardized full-field electroretinograms (ERGs) were performed before treatment and then at 2, 3 and 8 months during the treatment period. After terminating treatment the rabbits were sacrificed and the morphology of the sectioned retina was studied.
RESULTS: After eight months of treatment the full-field ERG demonstrated normal rod function in treated and control rabbits, but the light adapted 30 Hz flicker b-wave amplitude was significantly reduced in the treated rabbits. This was the case for both the light adapted (Wilcoxon signed ranks test, P = 0.046) and the dark adapted (Wilcoxon signed ranks test, P = 0.028) 30 Hz flicker response from the treated rabbits. Retinal immunohistology revealed a severe accumulation of GABA in amacrine cells and in the inner plexiform layer in 4 of 6 treated rabbits compared to the controls.
CONCLUSIONS: Topiramate, orally administrated to rabbits, may cause a significant reduction of the retinal function demonstrated by the reduced b-wave amplitude in the full-field ERG, as well as changes in immunohistology characterized by a severe accumulation of GABA in the inner retina. The retinal dysfunction and the morphological changes indicate that topiramat may damage the retina, similarly to vigabatrin (another anti-epileptic drug).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17111186     DOI: 10.1007/s10633-006-9027-8

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  57 in total

1.  Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects.

Authors:  F W Fraunfelder; F T Fraunfelder
Journal:  Ophthalmology       Date:  2004-07       Impact factor: 12.079

Review 2.  Antiepileptic drugs in mood-disordered patients.

Authors:  Prashant Gajwani; Anna Forsthoff; David Muzina; Benedikt Amann; Keming Gao; Omar Elhaj; Joseph R Calabrese; Heinz Grunze
Journal:  Epilepsia       Date:  2005       Impact factor: 5.864

Review 3.  Topiramate in migraine prophylaxis.

Authors:  D D'Amico; L Grazzi; S Usai; F Moschiano; G Bussone
Journal:  Neurol Sci       Date:  2005-05       Impact factor: 3.307

4.  Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study.

Authors:  Marius K Nickel; Cerstin Nickel; Patrick Kaplan; Claas Lahmann; Moritz Mühlbacher; Karin Tritt; Jakub Krawczyk; Peter K Leiberich; Wolfhardt K Rother; Thomas H Loew
Journal:  Biol Psychiatry       Date:  2005-03-01       Impact factor: 13.382

Review 5.  Bipolar mixed states and their treatment.

Authors:  Eduard Vieta
Journal:  Expert Rev Neurother       Date:  2005-01       Impact factor: 4.618

Review 6.  Preventive treatment of headaches.

Authors:  Stephen D Silberstein
Journal:  Curr Opin Neurol       Date:  2005-06       Impact factor: 5.710

7.  Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials.

Authors:  G Bussone; H-C Diener; J Pfeil; S Schwalen
Journal:  Int J Clin Pract       Date:  2005-08       Impact factor: 2.503

8.  Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin.

Authors:  Vesna Ponjavic; Lotta Gränse; Sten Kjellström; Sten Andréasson; Anitha Bruun
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

Review 9.  The effect of antiepileptic drugs on visual performance.

Authors:  Emma J Roff Hilton; Sarah L Hosking; Tim Betts
Journal:  Seizure       Date:  2004-03       Impact factor: 3.184

Review 10.  Towards the pharmacotherapy of eating disorders.

Authors:  Kristine J Pederson; James L Roerig; James E Mitchell
Journal:  Expert Opin Pharmacother       Date:  2003-10       Impact factor: 3.889

View more
  13 in total

Review 1.  Effects of Topiramate on afferent visual pathways: controversies and uncertainties.

Authors:  Seyed-Hossein Abtahi; Mohammad-Ali Abtahi; Masoud Etemadifar; Mehdi Mazloumi; Hossein Attarzadeh
Journal:  Neurol Sci       Date:  2012-05-19       Impact factor: 3.307

Review 2.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

3.  Topiramate and visual loss in a patient carrying a Leber hereditary optic neuropathy mutation.

Authors:  Steno Rinalduzzi; Anna Maria Cipriani; Neri Accornero
Journal:  Neurol Sci       Date:  2011-09-07       Impact factor: 3.307

4.  Evaluation of Ocular Side Effects in the Patients on Topiramate Therapy for Control of Migrainous Headache.

Authors:  Omid Hesami; Seyedeh Simindokht Hosseini; Nasim Kazemi; Seyed-Mostafa Hosseini-Zijoud; Nahid Beladi Moghaddam; Farhad Assarzadegan; Sara Mokhtari; Shahrzad Fakhraee
Journal:  J Clin Diagn Res       Date:  2016-03-01

5.  Electronegative electroretinogram associated with topiramate toxicity and vitelliform maculopathy.

Authors:  Irena Tsui; Daniel Casper; Chai Lin Chou; Stephen H Tsang
Journal:  Doc Ophthalmol       Date:  2007-10-03       Impact factor: 2.379

6.  Ocular adverse effects of Topiramate: Two case reports.

Authors:  Ananya Mandal; Suparna Chatterjee; Sagarmay Bose; Gautam Ganguly
Journal:  Indian J Pharmacol       Date:  2008-11       Impact factor: 1.200

7.  Topiramate and the vision: a systematic review.

Authors:  Mohammad-Ali Abtahi; Seyed-Hossein Abtahi; Farhad Fazel; Peyman Roomizadeh; Masoud Etemadifar; Keivan Jenab; Mojtaba Akbari
Journal:  Clin Ophthalmol       Date:  2012-01-12

8.  Massive bilateral choroidal detachment induced by administration of topiramate.

Authors:  Alireza Dehghani; Mohammad-Ali Abtahi; Seyed-Hossein Abtahi; Alireza Peyman; Masoud Etemadifar; Heshmatollah Ghanbari; Zahra Mohammadi
Journal:  Case Rep Ophthalmol       Date:  2011-08-09

9.  Topiramate-induced maculopathy in IgG4-related disease.

Authors:  Joanna DaCosta; Saad Younis
Journal:  Drug Healthc Patient Saf       Date:  2016-06-08

10.  Presumed topiramate retinopathy: a case report.

Authors:  Tiffany L M Yeung; Patrick S H Li; Kenneth K W Li
Journal:  J Med Case Rep       Date:  2016-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.